Trimethoprim and
Potassium Sparing Drugs: A Risk for Hyperkalemia
John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References
1. Velazquez H et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.
2. Medina I et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990;323:776-782.
3. Don BR. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects. Clin Nephrol. 2001;55:45-52.
4. Antoniou T et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system. Arch Intern Med. 2010;170:1045-1049.
5. Weir MA et al. Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: A nested case-control study. Clin J Am Soc Nephrol. 2010;5:1544-1551.
6. Wrenger E et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers; analysis of 44 cases. BMJ. 2003;327:147-149.